Our sites specialize in certain areas, products and regions. From our site in Alby-sur-Chéran, France, we manufacture a wide range of products including over-the-counter (OTC) and prescription topicals such as Soolantra®, Aklief®, Epiduo® and Metvix®. Our largest production site, at Baie-D’Urfé, Canada, is focused on the global supply of Cetaphil®, with additional production of OTC and prescription medicine for the U.S. market. The Latin American market is predominantly served by our site in Hortolândia, Brazil, which also supplies nearly 40 countries globally. Our Global Center of Excellence for Injectable Aesthetics in Uppsala, Sweden, specializes in the research and development, production and distribution of world-class aesthetics products, including Restylane®.
SECURING SUPPLY WITH PROVEN RESILIENCE
Alongside our in-house operations, we also outsource the production of selected products and formulations. We carefully assess third-party contract manufacturing organizations (CMOs) against our supplier framework, ensuring they meet our rigorous standards. We are investing significantly in U.S. manufacturing by expanding final assembly and packaging for our novel biologic in Florida, and manufacturing flagship Dermatological Skincare products through U.S.-based partners. We have committed to investing more than 650 million USD to U.S. manufacturing through 2030, strengthening Galderma’s presence in our largest market worldwide to support future growth.
By leveraging best-in-class technology, we are able to produce at a pace consistent with demand without compromising quality. Additionally, our unique Integrated Dermatology Strategy enables us to work on a common platform and therefore optimize our operations. We continuously look for ways to standardize manufacturing and packaging processes across all segments, helping save both time and resources.
We are also significantly expanding our manufacturing capabilities to meet growing global demand for Injectable Aesthetics. We are currently redeveloping our state-of-the-art facility in Uppsala to support both the distribution and development of new products, and Galderma’s growth trajectory. This includes the addition of new production lines to meet growing demand, with initial operations starting in 2026 and full capacity planned for 2027. We also invested in our Hortolândia site in 2025 to expand production capacity, strengthen existing capabilities and advance plans for a Center of Excellence, scheduled to open in 2027 to train healthcare professionals from across Latin America.
INDUSTRY-LEADING SAFETY AND QUALITY TRACK RECORD
All of Galderma’ manufacturing processes adhere to a variety of local and global laws and regulations, and all four of our sites have consistently passed all applicable material inspections.
These manufacturing plants are regularly audited by health authorities in their respective countries, including the U.S. Food and Drug Administration (FDA), Health Canada, the French National Agency for the Safety of Medicines and Health Products (ANSM) and Dekra. Our manufacturing facilities have also earned multiple certifications, such as ISO 14001 and ISO 45001, which reflect environmental, health and safety vigilance.
The key to our approach is continuous improvement. We hold regular quality and safety talks in our factories and continually analyze and learn from incidents at plants inside and outside the company. This has led to a constant and significant reduction in number and frequency of injuries.
Maintaining control over our production has enabled us to effectively implement and maintain sustainability measures. We use 90% renewable electricity across all our sites from a combination of solar, wind, hydropower, geothermal, biofuel and biomass. Currently, two of our four factories are certified Carbon Neutral, and we reduced our annual water withdrawal intensity by 15% in 2025 compared to 2024.
